Comment from QuantHealth, Ltd.
AnonymousSupportBusiness
Summary: QuantHealth, a clinical-AI company, supports the FDA's pilot program to examine AI-enabled optimization of early-phase clinical trials. They argue that patient-level simulations can improve decision quality, enhance participant safety by identifying risks before enrollment, and eventually provide a framework for accelerated approval and simulated control arms.
QuantHealth submits the attached comment in response to Docket No. FDA-2026-N-4390. QuantHealth is a clinical-AI company whose central capability is the patient-level simulation of clinical trials. The QuantHealth Platform is based on wide and deep data sources of 350M US patients, and millions of drug data points to predict how any single patient would respond to any drug in-silico. Unlike platforms oriented primarily toward drug discovery and design or clinical operations or site logistics, QuantHealth’s work is concentrated on the scientific question at the center of clinical development: what is a given trial likely outcome, and what does that imply for the patients who will enroll in it.
QuantHealth's comment focuses on the questions where we believe we have the most to contribute: decision quality, participant safety, AI system performance, trustworthiness, and comparative evaluation. We also include a forward look at two pathways by which validated trial simulation might, in time, contribute to the Agency's evidentiary frameworks for accelerated approval.
We welcome the opportunity to engage further with the Agency as the pilot is designed and implemented.
Francisco Beca, MD, PhD
Chief Medical Officer, QuantHealth